2 withdrawn, 1 completed, 1 not yet recruiting, 1 recruiting. 3 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Withdrawn 2, Recruiting 1 |
| Phase 2 | 2 | Completed 1, Not yet recruiting 1 |
Follow Recurrent Splenic Marginal Zone Lymphoma: new trials by email Literature Review of Recurrent Splenic Marginal Zone Lymphoma trials Research Report on Recurrent Splenic Marginal Zone Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing Mosunetuzumab Alone, With Zanubrutinib, or With Polatuzumab Vedotin for Treating Marginal Zone Lymphoma That Came Back or Didn't Get Better With Treatment Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Recurrent Nodal Marginal Zone Lymphoma | Phase 2 | Not yet recruiting | SWOG Cancer Research Network | 138 | 2026-10-03 | 2026-10-13 |
| Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Biopsy, Biospecimen Collection, Bone Marrow Aspiration - Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 1 | Recruiting | City of Hope Medical Center | 37 | 2025-08-25 | 2026-04-20 |
| Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma Lenalidomide, Ublituximab, Umbralisib - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Phase 1 | Withdrawn | Yazeed Sawalha | 2022-09-30 | 2022-09-30 | |
| Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin Lymphoma Acalabrutinib, Duvelisib - Recurrent Follicular Lymphoma, Recurrent Marginal Zone Lymphoma | Phase 1 | Withdrawn | Narendranath Epperla | 2022-07-01 | 2022-06-07 | |
| Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas Ibrutinib, Idelalisib, Laboratory Biomarker Analysis - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia | Phase 2 | Completed | Mayo Clinic | 65 | 2015-02-19 | 2026-06-24 |
Lymphoma, B-Cell, Marginal Zone (5) · Lymphoma, Follicular (4) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma, B-Cell (2) · Lymphoma, Mantle-Cell (2) · Waldenstrom Macroglobulinemia (2) · Lymphoma, Large B-Cell, Diffuse (1)
Hemic and Lymphatic Diseases (5) · Immune System Diseases (5) · Immunoproliferative Disorders (5) · Lymphatic Diseases (5) · Lymphoma (5) · Lymphoma, Non-Hodgkin (5) · Lymphoproliferative Disorders (5) · Neoplasms (5) · Neoplasms by Histologic Type (5) · Hematologic Diseases (3) · Lymphoma, B-Cell (3) · Blood Protein Disorders (2) · Cardiovascular Diseases (2) · Chronic Disease (2) · Disease Attributes (2)
Biopsy (2) · Magnetic Resonance Spectroscopy (2) · Specimen Handling (2) · zanubrutinib (2) · LFB-R603 (1) · Lenalidomide (1) · acalabrutinib (1) · duvelisib (1) · ibrutinib (1) · idelalisib (1) · pembrolizumab (1) · polatuzumab vedotin (1) · ublituximab (1) · umbralisib (1)
City of Hope Medical Center (1) · Mayo Clinic (1) · Narendranath Epperla (1) · SWOG Cancer Research Network (1) · Yazeed Sawalha (1)
United States (3)
Boyu Hu (1) · Geoffrey Shouse (1) · Narendranath Epperla, MD (1) · Wei Ding (1) · Yazeed Sawalha, MD (1)
P30CA033572 (1), P50CA097274 (1), U10CA180888 (1)